Home > Boards > US Listed > Biotechs > Aquestive Therapeutics Inc (AQST)

Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M Aquestive

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ADVFN_bioking Member Profile
 
Followed By 22
Posts 630
Boards Moderated 0
Alias Born 05/15/17
160x600 placeholder
Aquestive receives FDA feedback; to resubmit marketing application for Libervant Seeking Alpha - 2/25/2021 7:59:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2021 7:31:03 AM
Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback GlobeNewswire Inc. - 2/25/2021 7:30:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 2/22/2021 4:44:22 PM
Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March... GlobeNewswire Inc. - 2/17/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/9/2021 7:35:36 AM
Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy GlobeNewswire Inc. - 1/28/2021 7:30:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/21/2021 4:34:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/21/2021 8:41:01 AM
Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film fo... PR Newswire (US) - 1/21/2021 8:30:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/20/2021 6:05:35 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 1/8/2021 4:46:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/8/2021 7:01:03 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/7/2021 7:36:05 AM
Aquestive Therapeutics Provides Business Update GlobeNewswire Inc. - 1/7/2021 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 4:06:10 PM
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 1/4/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2020 7:00:55 AM
Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer GlobeNewswire Inc. - 12/16/2020 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 12/1/2020 6:01:05 AM
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire Inc. - 11/25/2020 9:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2020 7:15:57 AM
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization GlobeNewswire Inc. - 11/23/2020 7:00:00 AM
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant GlobeNewswire Inc. - 11/18/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2020 4:36:10 PM
ADVFN_bioking   Wednesday, 10/16/19 09:12:59 AM
Re: None
Post # of 143 
Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M Aquestive Therapeutics announced, in response to Indivior PLC's press release issued earlier today of Indivior's intent to cease production of its authorized generic buprenorphine-naloxone film product, that the company is reaffirming its full year 2019 total revenue guidance. Full year 2019 total revenue is now expected to be at the top end of the company's guidance range of $38M-$45M. Full year 2019 revenue from the company's Suboxone franchise is expected to be at the top end of its guidance range of $29M-$32M. As of October 2019, Suboxone and the authorized generic buprenorphine-naloxone film continue to retain approximately 75% of the market for film treatments of opioid dependence, of which a substantial majority of its retained market share is branded Suboxone.

Read more at:
https://thefly.com/landingPageNews.php?id=2975849

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences